Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B.
Kalafateli M. et al, (2025), Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial
Cooke GS. et al, (2025), The Lancet, 405, 1769 - 1780
Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure
Zhao L. et al, (2025), PLOS Pathogens, 21, e1012959 - e1012959
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms
Lumley SF. et al, (2025), Scientific Reports, 15
Reply to: “Understanding virologic heterogeneity in chronic hepatitis B treatment”
Matthews PC. et al, (2025), JHEP Reports, 7, 101280 - 101280
Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study
Perez-Campuzano V. et al, (2024), JHEP Reports, 6
Distinct Requirements for CD4<sup>+</sup> T Cell Help for Immune Responses Induced by mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines.
Yong L. et al, (2024), European journal of immunology
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
Colton H. et al, (2024), British journal of haematology
Prospective cohort for early detection of liver cancer (Pearl): a study protocol
Khanna K. et al, (2024), BMJ Open, 14, e085541 - e085541
Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] (The Lancet Regional Health - Europe (2023) 35, (S2666776223001667), (10.1016/j.lanepe.2023.100747))
Evans RA. et al, (2024), The Lancet Regional Health - Europe, 44
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom.
Garay OU. et al, (2024), Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim YJ. et al, (2024), British journal of haematology, 205, 440 - 451
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.
Davis C. et al, (2024), Vaccines, 12
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS. et al, (2024), The Lancet. Rheumatology, 6, e339 - e351
Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.
Hirschfield GM. et al, (2024), Hepatology communications, 8
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Ali M. et al, (2024), Clinical and Experimental Immunology